A Look at Daratumumab

Conference Correspondent - ASH 2016 - Multiple Myeloma
Leslie Lauersdorf, ARNP
Leslie Lauersdorf discusses her perceptions regarding daratumumab therapy and identifies how her patients have benefited from this treatment option.
Related Items
Updated Analysis of the Efficacy of Daratumumab Combination Therapy in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy
Conference Correspondent published on December 5, 2016 in ASH 2016 - Multiple Myeloma
Use of Montelukast to Reduce Infusion Reactions in Patients with Relapsed or Refractory Multiple Myeloma
Conference Correspondent published on December 5, 2016 in ASH 2016 - Multiple Myeloma
Efficacy of Daratumumab in Combination for Relapsed/Refractory Multiple Myeloma, Based on Previous Treatment Exposure
Conference Correspondent published on December 5, 2016 in ASH 2016 - Multiple Myeloma
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma in Patients with 1 to 3 Prior Lines of Therapy
Conference Correspondent published on December 5, 2016 in ASH 2016 - Multiple Myeloma
Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies
Conference Correspondent published on December 5, 2016 in ASH 2016 - Multiple Myeloma
Real-World Benefit Shown for Daratumumab Monotherapy versus Physician’s Choice
Conference Correspondent published on December 5, 2016 in ASH 2016 - Multiple Myeloma
Real-World Trends in Treatment Use, Healthcare Costs, and Overall Survival Among Patients with Multiple Myeloma
Conference Correspondent published on December 5, 2016 in ASH 2016 - Multiple Myeloma
Retreatment with Daratumumab Among Refractory Patients with Multiple Myeloma
Conference Correspondent published on December 4, 2016 in ASH 2016 - Multiple Myeloma
A New Risk Stratification Tool to Estimate Survival in Patients with Multiple Myeloma After First Relapse
Conference Correspondent published on December 4, 2016 in ASH 2016 - Multiple Myeloma
Daratumumab, Bortezomib, Dexamethasone in Relapsed/Refractory Multiple Myeloma: Updated Efficacy Analysis of CASTOR
Conference Correspondent published on December 4, 2016 in ASH 2016 - Multiple Myeloma
Last modified: March 16, 2017